1-12 of 12
Sort by
News

Researchers Identify Possible New Targets in CLL Subtypes

Thomas R. Collins
Published: 2023
Abstract
January Supplement 2024
View News titled, Researchers Identify Possible New Targets in CLL Subtypes
News

Global Real-World Patient Survey Identifies Need for Support, Patient Education in CLL

Anna Azvolinsky, PhD
Published: 2023
Abstract
January Supplement 2024
View News titled, Global Real-World Patient Survey Identifies Need for Support, Patient Education in CLL
News

Prognostic Testing Underused for Patients with CLL/SLL

Lara C. Pullen, PhD
Published: 2023
Abstract
January Supplement 2024
View News titled, Prognostic Testing Underused for Patients with CLL/SLL
News

Flow Cytometry Identified as Less Expensive Method to Learn IGHV Status in CLL

Thomas R. Collins
Published: 2023
Abstract
January Supplement 2024
View News titled, Flow Cytometry Identified as Less Expensive Method to Learn IGHV Status in CLL
News

Signs of Restored Immune System Seen After Ibrutinib, Venetoclax in Chronic Lymphocytic Leukemia

Thomas R. Collins
Published: 2023
Abstract
January Supplement 2024
View News titled, Signs of Restored Immune System Seen After Ibrutinib, Venetoclax in Chronic Lymphocytic Leukemia
News

CD19 CAR T-Cell Therapy for CLL Shows Durable Response

Published: 2023
Abstract
January Supplement 2024
View News titled, CD19 CAR T-Cell Therapy for CLL Shows Durable Response
News

Review Analyzes Cardiovascular Toxicities Associated With Bruton Tyrosine Kinase Inhibitors in CLL

Anna Azvolinsky, PhD
Published: 2023
Abstract
January Supplement 2024
View News titled, Review Analyzes Cardiovascular Toxicities Associated With Bruton Tyrosine Kinase Inhibitors in CLL
News

Nearly Two Decades of Data Show Long-Term Remissions From FCR for IGHV-Mutated Chronic Lymphocytic Leukemia

Leah Lawrence
Published: 2023
Abstract
January Supplement 2024
View News titled, Nearly Two Decades of Data Show Long-Term Remissions From FCR for IGHV-Mutated Chronic Lymphocytic Leukemia
News

Sequencing of Patient Samples Shows Genetic Events Linked to Venetoclax-Resistant CLL

Katie Robinson
Published: 2023
Abstract
January Supplement 2024
View News titled, Sequencing of Patient Samples Shows Genetic Events Linked to Venetoclax-Resistant CLL
News

High Karyotypic Complexity, Isolated Translocations Are Prognostic Factors in Venetoclax-Treated CLL

Katie Robinson
Published: 2023
Abstract
January Supplement 2024
View News titled, High Karyotypic Complexity, Isolated Translocations Are Prognostic Factors in Venetoclax-Treated CLL
News

Detailed Safety Analysis Underscores Superiority of Acalabrutinib vs. Ibrutinib

Lara C. Pullen, PhD
Published: 2023
Abstract
January Supplement 2024
View News titled, Detailed Safety Analysis Underscores Superiority of Acalabrutinib vs. Ibrutinib
News

PI3K Inhibitors: A Series of Unfortunate Events

Leah Lawrence
Published: 2023
Abstract
January Supplement 2024 PI3K inhibitors were once a promising class of drugs for CLL. Now, their stock has fallen in favor of newer therapies.
View News titled, PI3K Inhibitors: A Series of Unfortunate Events